JPRN-jRCT1080220286未知4 期
Post-Marketing Clinical Study of EPZICOM Tablet (Lamivudine / Abacavir Sulfate) -Pharmacokinetic Study in HIV-Infected Patients
GlaxoSmithKline K.K.0 个研究点开始时间: 2006年8月2日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 65age old（—）
- 性别
- All
入选标准
- •Main inclusion criteria:
- •- A Japanese HIV-infected patient who continues to use one EPZICOM tablet in the morning at least for 2 weeks prior to administration of the study drug.
- •- A patient who agrees to abstain from alcohol from 48 hours prior to administration of the study drug until completion of blood sampling for pharmacokinetic analysis.
- •Main exclusion criteria:
- •- A patient developing AIDS
- •- A patient with a history of hypersensitivity to the study drug and the ingredients (lamivudine, abacavir sulfate) of the study drug
排除标准
- 未提供
研究者
相似试验
已完成
4 期
Pharmacokinetic Study Of EPZICOM TabletHIV InfectionNCT00337922GlaxoSmithKline8
未知
4 期
Post-Marketing Clinical Study of ReQuip Tablets in Patients with Parkinson's Disease -Evaluation of Long-Term Efficacy and SafetyParkinson's DiseaseJPRN-jRCT1080220387GlaxoSmithKline K.K.100
未知
4 期
Post-marketing Clinical Study of Onglyza TabletJPRN-jRCT1080222299Kyowa Hakko Kirin Co., Ltd.
未知
Unknown
Open-label, multicenter study to evaluate the safety and efficacy of oral etoposide and iv cisplatin for patients with advanced or recurrent cervical cancerCervical cancerJPRN-jRCT2080221037ippon Kayaku Co., Ltd.40
已完成
不适用
Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®Diabetes Mellitus, Type 2NCT04469855Novo Nordisk A/S3,217